Jitendra Wadhane - 03 Aug 2022 Form 3 Insider Report for Pyxis Oncology, Inc. (PYXS)

Role
SVP, Chief Accounting Officer
Signature
/s/ Pamela Connealy, Attorney-in-Fact for Jitendra Wadhane
Issuer symbol
PYXS
Transactions as of
03 Aug 2022
Net transactions value
$0
Form type
3
Filing time
09 Aug 2022, 16:34:38 UTC
Next filing
28 Mar 2023
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
holding PYXS Common Stock 43,648 03 Aug 2022 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding PYXS Stock Option (Right to buy) 03 Aug 2022 Common Stock 157,257 $8.71 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents restricted stock units that vest 25% on March 31, 2023, and then in 36 substantially-equal monthly installments thereafter, subject to the reporting person's continued employment through the applicable vesting date.
F2 These stock options vest 25% on August 23, 2022, and then in 36 substantially-equal monthly installments thereafter, subject to the reporting person's continued employment through the applicable vesting date.

Remarks:

Exhibit List: Exhibit 24 - Power of Attorney